Effect of hypertension (HTN) on progression-free survival (PFS) in patients (pts) receiving front-line bevacizumab (BEV) for primary advanced ovarian cancer (OC) in the NOGGO single-arm OTILIA study: A post hoc analysis in 808 pts.

Armbrust, R., Wimberger, P., Mustea, A., Oskay-Özcelik, G., Keller, M., Richter, R., Harde, J., Zortel, M., Wegenaer, A., Tome, O., Sehouli, J., North-Eastern German Society of Gynaecological Oncology (NOGGO), 2018.

J Clin Oncol (Meeting Abstracts) 36 (suppl) abstr 5546.